[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.92.62. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Correspondence
September 2010

Will Symptomatic Intracerebral Hemorrhages Decrease Among Eligible Dabigatran-Treated Patients Who Receive Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke?

Author Affiliations

Author Affiliation: Section of Neurology, Department of Internal Medicine, Far-Eastern Memorial Hospital, Ban-Ciao City, Taipei County, Taiwan.

Arch Neurol. 2010;67(9):1156-1157. doi:10.1001/archneurol.2010.205

Current guidelines strongly recommend warfarin for patients with atrial fibrillation and moderate to high risk of stroke, such as those with mitral stenosis or prosthetic heart valve, a history of prior ischemic stroke or systemic embolism, or 2 or more thromboembolic risk factors.1 In the National Institute of Neurological Disorders and Stroke, patients with warfarin treatment are excluded from intravenous tissue plasminogen activator if international normalized ratio (INR) is high (INR > 1.3 in 1995,2 or INR > 1.7 in 20053,4). However, Prabhakaran and colleagues5 revealed a nearly 10-fold higher rate of symptomatic intracranial hemorrhage among patients who were taking warfarin, even with a lower INR (median, 1.04). In the Randomized Evaluation of Long Term Anticoagulant Therapy study,6 dabigatran etexilate demonstrated its effectiveness in prevention of systemic embolism and future stroke with a similar safety profile to warfarin. Will dabigatran-treated patients have a lower risk of symptomatic intracerebral hemorrhage while receiving tissue plasminogen activator treatment for acute ischemic stroke, or should we wait for more evidence?

First Page Preview View Large
First page PDF preview
First page PDF preview
×